Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

Open Access 01-12-2020 | Sarcoidosis | Case report

Extensive eye-oral-bronchial mucosal nodules with eosinopgillia: a rare case report and literature review

Authors: Lujin Wu, Qianru Leng, Yan Wang, Daowen Wang, Danlei Yang

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Mucosal nodules can be caused by infection, inflammation and neoplastic disease. Many noninfectious diseases, such as eosinophilia, amyloidosis, sarcoidosis, Wegener’s granuloma, langerhans cell histiocytosis etc., are associated with the formation of multisytem mucosal nodules, especially significant bronchial lesions. Detailed medical history, comprehensive metabolic profile, biopsy specimen and imaging examinations are required for differentiating among these disorders. The process of diagnosis and treatment of our patient’s mucosal nodules was challenging, which could be helpful to similar cases.

Case presentation

We represent a case of a 29-year-old woman with plentiful nodules of unknown origin on extensive mucous membranes. Biopsy specimen reports inflammatory lesions with large numbers of neutrophils, lymphocytes, and varying degrees of eosinophils. Treatment of anti-infection, anti-tussive and anti-allergic was ineffective, but glucocorticoid showed great improvement to her symptoms.

Conclusion

We experienced a rare case with plentiful nodules of unknown origin on extensive mucous membranes. She may be a specific phenotype of eosinophilia or may be a novel multisystem disease with respiratory system as the primary symptom. The diagnosis of our patient remains unclear, but tentative glucocorticoid therapy was beneficial.
Literature
1.
go back to reference Ma D, Li DG, Zhang X, He L. The prevention and treatment on rare diseases in China: opportunities and challenges. Chinese J Evidence Based Pediatr. 2011;6:81–2 (in Chinese). Ma D, Li DG, Zhang X, He L. The prevention and treatment on rare diseases in China: opportunities and challenges. Chinese J Evidence Based Pediatr. 2011;6:81–2 (in Chinese).
2.
go back to reference Harari S, Cottin V, Humbert M. Global effort against rare and orphan diseases. Eur Respir Rev. 2012;21(125):171–2.PubMedCrossRef Harari S, Cottin V, Humbert M. Global effort against rare and orphan diseases. Eur Respir Rev. 2012;21(125):171–2.PubMedCrossRef
3.
go back to reference Pogue RE, et al. Rare genetic diseases: update on diagnosis, treatment and online resources. Drug Discov Today. 2018;23(1):187–95.PubMedCrossRef Pogue RE, et al. Rare genetic diseases: update on diagnosis, treatment and online resources. Drug Discov Today. 2018;23(1):187–95.PubMedCrossRef
4.
5.
6.
go back to reference Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med. 2013;1(6):479–87.PubMedCrossRef
7.
go back to reference Harari S, et al. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Eur Respir Rev. 2015;24(137):375–7.PubMedCrossRef Harari S, et al. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Eur Respir Rev. 2015;24(137):375–7.PubMedCrossRef
9.
go back to reference Butt NM, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–72.PubMedCrossRef Butt NM, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–72.PubMedCrossRef
10.
go back to reference Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80(1):75–83.PubMedCrossRef Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80(1):75–83.PubMedCrossRef
11.
go back to reference Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–59.PubMedCrossRef Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–59.PubMedCrossRef
12.
go back to reference Montgomery ND, et al. Diagnostic complexities of eosinophilia. Arch Pathol Laboratory Med (1976). 2013;137(2):259–69.CrossRef Montgomery ND, et al. Diagnostic complexities of eosinophilia. Arch Pathol Laboratory Med (1976). 2013;137(2):259–69.CrossRef
13.
go back to reference Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468–92.PubMedCrossRef Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468–92.PubMedCrossRef
14.
go back to reference Singhal S, et al. Hematological parameters in patients of cleft lip and cleft palate with special reference to eosinophil counts. J Craniofac Surg. 2014;25(1):103–5.PubMedCrossRef Singhal S, et al. Hematological parameters in patients of cleft lip and cleft palate with special reference to eosinophil counts. J Craniofac Surg. 2014;25(1):103–5.PubMedCrossRef
15.
go back to reference Dvivedi J, Dvivedi S. A clinical and demographic profile of the cleft lip and palate in sub-Himalayan India: a hospital-based study. Indian J Plast Surg. 2012;45(1):115–20.PubMedPubMedCentralCrossRef Dvivedi J, Dvivedi S. A clinical and demographic profile of the cleft lip and palate in sub-Himalayan India: a hospital-based study. Indian J Plast Surg. 2012;45(1):115–20.PubMedPubMedCentralCrossRef
16.
go back to reference Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology. 2015;2015(1):92–7.PubMedCrossRef Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology. 2015;2015(1):92–7.PubMedCrossRef
17.
go back to reference Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.PubMedPubMedCentral Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.PubMedPubMedCentral
18.
go back to reference Sinico RA, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.PubMedCrossRef Sinico RA, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.PubMedCrossRef
19.
go back to reference Sablé-Fourtassou R, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef Sablé-Fourtassou R, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef
21.
go back to reference Wakasa K, et al. Primary tracheobronchial amyloidosis. A case report and review of reported cases. Acta Pathol Jpn. 1984;34(1):145–52.PubMed Wakasa K, et al. Primary tracheobronchial amyloidosis. A case report and review of reported cases. Acta Pathol Jpn. 1984;34(1):145–52.PubMed
22.
go back to reference Gibbaoui H, Abouchacra S, Yaman M. A case of primary diffuse tracheobronchial amyloidosis. Ann Thorac Surg. 2004;77(5):1832–4.PubMedCrossRef Gibbaoui H, Abouchacra S, Yaman M. A case of primary diffuse tracheobronchial amyloidosis. Ann Thorac Surg. 2004;77(5):1832–4.PubMedCrossRef
23.
go back to reference Ozer C, et al. Primary diffuse tracheobrochial amyloidosis: case report. Eur J Radiol. 2002;44(1):37–9.PubMedCrossRef Ozer C, et al. Primary diffuse tracheobrochial amyloidosis: case report. Eur J Radiol. 2002;44(1):37–9.PubMedCrossRef
24.
go back to reference Li D, et al. Primary tracheobronchial amyloidosis: coronal CT scan may provide clues for early diagnosis. J Postgrad Med. 2013;59(3):223–5.PubMedCrossRef Li D, et al. Primary tracheobronchial amyloidosis: coronal CT scan may provide clues for early diagnosis. J Postgrad Med. 2013;59(3):223–5.PubMedCrossRef
26.
go back to reference Lu X, et al. Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China. Biomed Res Int. 2017;2017:3425812.PubMedPubMedCentral Lu X, et al. Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China. Biomed Res Int. 2017;2017:3425812.PubMedPubMedCentral
27.
go back to reference Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72(10):937–45.PubMedCrossRef Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72(10):937–45.PubMedCrossRef
28.
go back to reference Roden AC, Yi ES. Pulmonary Langerhans cell Histiocytosis: an update from the Pathologists’ perspective. Arch Pathol Lab Med. 2016;140(3):230–40.PubMedCrossRef Roden AC, Yi ES. Pulmonary Langerhans cell Histiocytosis: an update from the Pathologists’ perspective. Arch Pathol Lab Med. 2016;140(3):230–40.PubMedCrossRef
29.
go back to reference Dimmler A, et al. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch. 2017;470(4):429–35.PubMedCrossRef Dimmler A, et al. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch. 2017;470(4):429–35.PubMedCrossRef
30.
go back to reference Lommatzsch M, et al. Bronchoalveolar lavage for the diagnosis of pulmonary Langerhans cell histiocytosis. Respir Med. 2016;119:168–74.PubMedCrossRef Lommatzsch M, et al. Bronchoalveolar lavage for the diagnosis of pulmonary Langerhans cell histiocytosis. Respir Med. 2016;119:168–74.PubMedCrossRef
31.
go back to reference Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483–7.PubMedCrossRef Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483–7.PubMedCrossRef
32.
go back to reference Patten SF, Tomecki KJ. Wegener’s granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol. 1993;28(5 Pt 1):710–8.PubMedCrossRef Patten SF, Tomecki KJ. Wegener’s granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol. 1993;28(5 Pt 1):710–8.PubMedCrossRef
33.
go back to reference Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol. 1996;17(4):785–92.PubMed Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol. 1996;17(4):785–92.PubMed
34.
go back to reference Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Med Interne (Paris). 1998;149(5):280–6. Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Med Interne (Paris). 1998;149(5):280–6.
35.
go back to reference Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004;70(2):312–22.PubMed Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004;70(2):312–22.PubMed
36.
go back to reference Costabel U, Hunninghake GW. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55. Costabel U, Hunninghake GW. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.
37.
go back to reference Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10):840–8.PubMed Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10):840–8.PubMed
38.
go back to reference Callister ME, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(Suppl 2):ii1–ii54.PubMedCrossRef Callister ME, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(Suppl 2):ii1–ii54.PubMedCrossRef
Metadata
Title
Extensive eye-oral-bronchial mucosal nodules with eosinopgillia: a rare case report and literature review
Authors
Lujin Wu
Qianru Leng
Yan Wang
Daowen Wang
Danlei Yang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01340-2

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.